

Hybrigenics presents new results on the specificity of inecalcitol in acute myeloid leukemia and multiple myeloma at AACR 2017

- Inhibition of proliferation of human leukemic cell lines
- Differentiation of cancer cells into less invasive and more functional cell types

Paris, France, on April 3rd, 2017 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments of proliferative diseases, announces the poster presentation of new results detailing the specificity of inecalcitol activities on human acute myeloid leukemia (AML) and multiple myeloma (MM) cell lines, today at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C.

Hybrigenics' research team has documented the effects of inecalcitol on four AML and four MM human cell lines *in vitro*. In addition to inhibition of cancer cell proliferation, its classical cytostatic activity, inecalcitol markedly "differentiates", i.e. transforms the cancer cells into less invasive and more normal functional cell types.

Inecalcitol decreases the AML and MM cell surface density of CD44 and CD49d, two biomarkers involved in the spreading and hiding of these cancer cells in the bone marrow, spleen and lymph nodes when it increases the AML cell surface density of CD11b and CD14, two biomarkers specific of monocytes and macrophages, the normal cell types in charge of fighting infections. Furthermore, inecalcitol even stimulates the secretion of cathelicidin, a natural human antimicrobial peptide, in all AML differentiated cells and in some MM cells.

"These results support our ongoing clinical Phase II study of inecalcitol in Acute Myeloid Leukemia. They provide several convergent mechanisms by which inecalcitol may extend overall survival, the primary endpoint. Furthermore, finding similar results on human Multiple Myeloma cell lines encourage us to investigate which therapeutic role could inecalcitol play in this new indication," said Remi Delansorne, Hybrigenics' CEO.

<http://www.abstractsonline.com/pp8/#!/4292/presentation/9413>

About Hybrigenics

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases.

Hybrigenics' development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Inecalcitol has been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States. Two clinical Phase II studies of inecalcitol are currently ongoing in chronic myeloid leukemia and acute myeloid leukemia. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere[®], which is the current gold-standard chemotherapeutic treatment for this indication.

Hybrigenics' research program is exploring the role of enzymes called Ubiquitin-Specific Proteases (USP) in the balance between degradation and recycling of proteins called onco-proteins due to their involvement in various cancers. Hybrigenics is evaluating the interest of inhibitors of USP as anti-cancer drug candidates. Hybrigenics has collaborated with Servier on one particular USP in oncology. In this R&D program, two milestones have been reached and additional milestones may be achieved until registration of a potential drug.

Hybrigenics Pharma Inc., based in Cambridge, Mass., is the U.S. subsidiary of Hybrigenics.



Hybrigenics is listed on the Alternext market of Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG



Hybrigenics

Rémi Delansorne

CEO

Tel.: +33 (0)1 58 10 38 00

investors@hybrigenics.com

NewCap

Financial communication

Julien Perez / Pierre Laurent

Tel.: +33 (0)1 44 71 94 94

hybrigenics@newcap.eu

Warning:

This press release contains certain forward-looking statements concerning Hybrigenics and its business. Such forward-looking statements are based on assumptions that Hybrigenics considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Hybrigenics filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number R.15-076 on October 22, 2015 (a copy of which is available on www.hybrigenics.com) and to the development of economic conditions, financial markets and the markets in which Hybrigenics operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Hybrigenics or not currently considered material by Hybrigenics. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Hybrigenics to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Hybrigenics shares in any country.